REGULATORY APPROVAL OF ORPHAN DRUGS IN USA

Main Article Content

S. S. TARUN NAG
V. BALAMURALIDHAR
C. PRATHIMA

Abstract

Orphan drugs are medicines or vaccines intended to treat, prevent or diagnose a rare disease (viz., Huntington's disease, myoclonus disease, Tourette syndrome, etc.). The definition of rare diseases varies across jurisdictions but typically considers disease prevalence, severity, and existence of alternative therapeutic options. A rare disease is not universal and depends on the legislation and policies adopted by each region or country. In the last 35 years, ODA (Orphan Drug Act, 1983) has been adopted in several countries worldwide (USA, Australia, European Union, Japan, etc.) and has successfully promoted R and D investments to develop new pharmaceutical products for the treatment of rare diseases. The incidences of such diseases have been increasing at a greater pace than the speed with which drugs are researched and developed to treat such diseases. One of the major reasons is that the pharmaceutical industry is not very keen in the development of orphan drugs as these drugs do not capture a bigger market. This is the current scenario in-spite of the various incentives provided in the orphan drug act. It was revealed that more to focus on existing regulations, Principles of rare disease & Drugs and integrated approaches utilized by various countries namely USA, EU, Canada, and Australia.

Keywords:
Rare diseases, orphan drugs, orphan drug act

Article Details

How to Cite
NAG, S. S. T., BALAMURALIDHAR, V., & PRATHIMA, C. (2021). REGULATORY APPROVAL OF ORPHAN DRUGS IN USA. Journal of International Research in Medical and Pharmaceutical Sciences, 16(1), 19-25. Retrieved from https://ikpresse.com/index.php/JIRMEPS/article/view/6126
Section
Review Article

References

Thaker Z. Thaker K, Jethva, Bhatt D, Zaveri M, Deshpande S. Orphan drugs: overview and regulatory review process. Int J Pharm Sci Res. 2019;10(2):505-18.

Orphan drugs [Internet] available orphan product development
Available:https://http://fda.gov/orphand

ownloads/drugs/developmentapproval process/.pdf
[Accessed on 19/10/2020].

Richter T, Nestler PS, Babela SR, Khan ZM, Tesoro T, Molsen E, Hughes DA. Rare disease terminology and definitions. A Systematic Global Review. Valuein Health. 2015;18:906-914.

FDA CDER Office of new drugs. Rare Diseases Program; 2020.
Available:https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTob acco/CDER/ucm221 248.htm
Available:https://pubmed.ncbi.nlm.nih.gov/28712612/

Russell JT, Thomas FU, Gigi H. Access and availability of orphan drugs in the United States: advances or cruel hoaxes. Expert Opinion on Orphan Drugs. 2014;2(11):1147-50.